Pharma BD Deal Intelligence
Bayer's $21.5B all-cash outbidding of Merck KGaA for Schering handed it Yasmin/YAZ, Betaferon, and a stake in Nexavar—diversifying beyond generics into women's health, oncology, and diagnostic imaging. The Magnevist and Mirena additions rounded out a franchise mix that held up well over time.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Schering CEO Hubertus Erlen stated both businesses are complementary and follow the same strategy, together they will be even more competitive internationally
Bayer AG successfully completed its takeover of Schering AG, controlling 88 percent of outstanding shares, with the merged entity Bayer Schering Pharma…
Bayer HealthCare turnover rose 46% to 11.7 billion euros on the back of the Schering acquisition, with the pharmaceuticals business up nearly 84% to…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Bayer acquired Schering AG for approximately EUR 17 billion (~$21.5 billion) in an all-cash tender offer, outbidding rival Merck KGaA to gain Schering's strong portfolio in women's health (Yasmin), diagnostic imaging (Magnevist), and oncology pipeline including Nexavar.
76K US cases/yr · $5.0B Global Targeted Oncology Market (2006, kidney/liver)
Renal cell carcinoma accounts for ~85% of kidney cancers (~81,000 new US cases and 14,500 deaths annually); 5-year survival is ~75% for localized disease, much lower for metastatic disease. Multiple sclerosis is a chronic autoimmune demyelinating disease of the CNS affecting ~1 million US adults, typically relapsing-remitting, causing progressive neurologic disability.
Nexavar entered the kidney cancer market alongside Pfizer's Sutent (sunitinib) in 2006, both pioneering targeted therapies. In MS, Betaferon competed with Biogen's Avonex and Rebif, and Teva's Copaxone. Nexavar would grow to peak revenues of $1.1B, while the MS landscape shifted dramatically toward oral therapies (Gilenya) in subsequent years.
$18.0B Global Contraceptive Market (2006)
Contraception encompasses hormonal methods (combined and progestin-only oral contraceptives, transdermal patches, injectables, implants, hormonal IUDs), non-hormonal copper IUDs, barrier methods, and permanent sterilization. Hormonal methods prevent ovulation and alter cervical mucus and endometrium; typical-use failure rates range from <1% (IUD, implant) to ~7-9% (pills).
Hormonal contraception competitive landscape: Yasmin/YAZ (drospirenone/ethinyl estradiol, Bayer) compete with J&J's Ortho Tri-Cyclen (norgestimate/EE) and generics; long-acting reversibles include Bayer's Mirena/Kyleena (levonorgestrel IUD), Merck's Nexplanon (etonogestrel implant), and CooperSurgical's Paragard (copper IUD, non-hormonal). Depo-Provera (medroxyprogesterone, Pfizer) is the leading injectable.
Bayer outbids Merck KGaA, which had launched an unsolicited EUR 77/share offer for Schering AG, winning the takeover battle with a higher premium.
Bayer announces public takeover offer for Schering AG at EUR 86/share (total ~EUR 16.5B / ~$22B), targeting Schering contraceptive portfolio (Yasmin) and specialty pharma pipeline.
Schering AG shareholders tender shares through the acceptance period ending May 31, 2006, exceeding the 75% minimum acceptance threshold required to proceed.
Bayer achieves 92.4% ownership of Schering AG shares and begins consolidating Schering revenues. H2 2006 Schering contribution adds EUR 3.1B to Bayer sales.
The combined pharmaceutical business is officially registered as Bayer Schering Pharma AG in the commercial register, completing the organizational merger.
Bayer HealthCare Pharmaceuticals division reaches EUR 7.5B in 2006 sales (up 83.9% YoY), driven by the Schering portfolio including Yasmin, Betaferon, and specialty oncology.
Bayer won a competitive bidding war and successfully integrated Schering AG, adding contraceptives (Yasmin/YAZ), MS (Betaferon), and radiology to its healthcare platform. The pharma division nearly doubled in size. Long-term, Bayer Pharma became a top-15 global pharma company, though the later Monsanto acquisition would overshadow this success.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Schering AG (this deal) | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
| Bayer AG / Asklepios BioPharmaceuticals | 2020 | $2.0B | 49 |
← Browse all deals · How we score deals
More: 2006 deals · Bayer AG deals · Dermatology deals